Search results
researchgate.net
- Evidence suggests that dual bronchodilation has greater and consistent efficacy for lung function and symptoms than mono-bronchodilation, whilst potentially reducing the risk of exacerbations and disease deterioration, with a similar safety profile to mono-bronchodilators.
www.ncbi.nlm.nih.gov/pmc/articles/PMC9489138/
People also ask
How effective is dual bronchodilation?
When is dual bronchodilation recommended?
Is dual bronchodilator therapy effective for chronic obstructive pulmonary disease?
Oct 28, 2020 · Finally, in order to optimize pharmacotherapy in stable COPD, we propose an algorithm on performing step-up of therapy from dual bronchodilation to triple therapy and step down from triple to double bronchodilation taking into account the extremely heterogeneous population of COPD patients.
- Andriana I Papaioannou, Stelios Loukides, Petros Bakakos, Epameinondas N Kosmas, Nikoletta Rovina, P...
- 10.2147/COPD.S273987
- 2020
- 2020
Jan 14, 2022 · • Which patients might benefit most from dual bronchodilation or triple therapy; • Whether triple therapy may affect mortality in patients with COPD; • Whether and when it is possible to de-escalate triple therapy maintaining the patient on dual bronchodilation therapy;
To investigate this, in this review we discuss: 1) current COPD treatment goals and their appropriateness for long-term COPD management; 2) evidence for dual- versus mono-bronchodilation as initial maintenance therapy in COPD; and 3) key evidence gaps in the optimal approach to initial bronchodilator therapy in COPD.
- Dave Singh, James F. Donohue, Isabelle H. Boucot, Neil C. Barnes, Chris Compton, Fernando J. Martine...
- 2021
New guidelines emphasize combination bronchodilators as a mainstay of therapy for many patients with symptomatic COPD and there are several new combination bronchodilator therapies available to patients.
- Steven D. Deas, Nikhil Huprikar
- 2017
Nov 1, 2020 · Dual bronchodilator therapy with a long-acting muscarinic antagonist (LAMA) and a long-acting β 2 -agonist (LABA) is recommended in the pharmacological management of chronic obstructive pulmonary disease (COPD) according to the Global Initiative for Chronic Obstructive Lung Disease.
- Antonio Anzueto, Alan Kaplan
- 2020
Nov 7, 2023 · Treatment guidelines for chronic obstructive pulmonary disease (COPD) recommend dual bronchodilator therapy for the majority of patients, consisting of an inhaled combination of long-acting β 2 -agonist (LABA) and long-acting muscarinic antagonist (LAMA).
Jan 3, 2018 · We review the rationale behind fixed-dose dual bronchodilator therapy, evidence for the 4 currently Food and Drug Administration-approved long-acting anticholinergic bronchodilators/long-acting β 2-agonists fixed combinations, patient suitability for the available inhaler devices, and practical guidance to optimize personalized care for ...
